Insmed Incorporated - Common Stock (INSM)

NetworkNewsWire Editorial Coverage : As America’s population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration’s “Make America Healthy Again” initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is making strides with its HyBryte(“TM”) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (“CTCL”), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte’s active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…

EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END

The CPI report sparked a massive sector rotation; investors are shedding overbought big tech names like Microsoft and NVIDIA in favor of risk-on assets.

Emerald Advisers, LLC celebrated 30 years of managing client funds in 2022, and its portfolio managers and research analysts help kick off 2023 by presenting their insights and outlook for the new year at the 30th Annual Groundhog Day Investment Forum on February 2nd in King of Prussia, PA.